Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma.

[1]  E. Van Cutsem,et al.  NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). , 2023, Journal of Clinical Oncology.

[2]  Joon-Oh Park,et al.  Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Reni,et al.  Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey , 2021, ESMO open.

[4]  C. Lepage,et al.  Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Reni,et al.  Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort , 2021, ESMO open.

[6]  M. Reni,et al.  Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients , 2020, Cancer Chemotherapy and Pharmacology.

[7]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[8]  M. Reni,et al.  Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. , 2018, The lancet. Gastroenterology & hepatology.

[9]  Yongkun Sun,et al.  Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial , 2018, Cancer Chemotherapy and Pharmacology.

[10]  L. Zitvogel,et al.  Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy , 2015, Oncoimmunology.

[11]  N. André,et al.  Metronomics: towards personalized chemotherapy? , 2014, Nature Reviews Clinical Oncology.

[12]  M. Reni,et al.  Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. , 2013, European journal of cancer.

[13]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[14]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[15]  L. Bracci,et al.  Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. , 2011, Cancer research.

[16]  M. Reni,et al.  Carbohydrate antigen 19‐9 change during chemotherapy for advanced pancreatic adenocarcinoma , 2009, Cancer.

[17]  A. Goldhirsch,et al.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  V. Khoo,et al.  Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. , 2007, The Journal of urology.

[19]  S. Baruchel,et al.  High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[20]  P. Cano,et al.  Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors , 2006, Clinical Cancer Research.

[21]  A. Goldhirsch,et al.  Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  R. Kerbel,et al.  Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. , 2005, Blood.

[23]  M. Loeffler,et al.  Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. , 2005, Cancer research.

[24]  R. Kalluri,et al.  Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression , 2004, Cancer Research.

[25]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[26]  A. Harris,et al.  Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. , 2003, Cancer research.

[27]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[28]  Peter Bohlen,et al.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .

[29]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[30]  S. Groshen,et al.  Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.